Surabhi Dangi-Garimella, PhD

The paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors.

On World Cancer Day, The American Journal of Managed Care would like to acknowledge the determination of cancer survivors and the support provided by various organizations to patients and their families.

Rising drug prices, the effect on the healthcare system, consumer push-back, and possible solutions were debated by the expert panel.

Pediatric oncologists from across the country covened a task force to develop an ethical framework that guides decisions on allocation based on curability, prognosis, and the incremental importance of a drug to a patient’s outcome

The generic manufacturer may try to maximize profits during the initial exclusivity period, says an expert from a leading health plan.

With increasing evidence of comparable efficacy and reduced toxicity of proton beam therapy, payers may have to reevaluate coverage policies.

Mortality in adolescent and young adult Hodgkin lymphoma patients is significantly affected by ethnic and socioeconomic factors, as well as insurance status, according to a new study published in Cancer Epidemiology, Biomarkers & Prevention.

At the annual meeting of the American Society of Hematology, physicians gathered to discuss the impact of alternate payment models on clinical practice.

A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

Learn where clinical care pathways stand today and what the future holds with respect to developing and implementing them.

The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.

A review by an independent Data Monitoring Committee found that nivolumab improved overall survival in patients with squamous cell carcinoma of the head and neck, compared with the control arm.

A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.

Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.

Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.

A study published in the Journal of Clinical Oncology has found that smoking before and after diagnosis of breast cancer is associated with increased mortality from breast cancer as well as other conditions, including respiratory and cardiovascular disease.

The Biologics License Application for the tumor necrosis factor alpha blocker, ABP 501, was submitted following results from a phase 3 study in 500 patients with moderate to severe plaque psoriasis and rheumatoid arthritis.

Personalized medicine has been the mantra in healthcare for quite some time, but finding health plans with blanket coverage policies for diagnostic testing is a struggle.

An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.

At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.

Thirteen hematologists on the American Society of Hematology(ASH)'s Choosing Wisely Task Force chose the top 5 of 380 recommendations listed by 70 other societies for presentation at ASH.

The authors of the study recommend lowering the screening age for colorectal cancer (CRC), especially for first-degree relatives of CRC patients and those with a genetic predisposition to the disease.

Carfilzomib has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.

A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.

An estimated 15.7% of individuals 65 or older may have received nonrecommended screenings for prostate and breast cancer, according to a new study published in JAMA Oncology.

At the 57th annual meeting of the American Society of Hematology, oncologists discussed trial data evaluating combination therapies for multiple myeloma and lymphoma.

A retrospective analysis of data from the National Cancer Data Base has found that patients who had cancer surgery at 56 days after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.

A study presented at the 2016 Cancer Survivorship Symposium hosted by the American Society of Clinical Oncology has identified significant uncertainty on who is responsible for the care of cancer survivors.